Investigational drug · Phase 2
Azeliragon
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
16
Any phase or sponsor naming "Azeliragon"
First trial start
2023
Sep 5, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Azeliragon", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Glioblastoma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Azeliragon" as an intervention, largest first.
- Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's DiseasePivotal-lookingTerminated
vTv TherapeuticsIndustry
NCT02080364 · 880 participants · Start Apr 2015 · Primary completion Jun 1, 2018
Drug: Azeliragon; Placebo · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Bellflower, California · 115 sites in all
- 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)Pivotal-lookingTerminated
vTv TherapeuticsIndustry
NCT02916056 · 297 participants · Start Dec 2016 · Primary completion Jun 1, 2018
Drug: Azeliragon 5mg · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Bellflower, California · 71 sites in all
- A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or PneumoniaPivotal-lookingActive, not recruiting
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT05815485 · 144 participants (planned) · Start May 4, 2023 · Primary completion Apr 2026
Drug: Azeliragon; Placebo · For: COVID-19
Sites: Chicago, Illinois; Ann Arbor, Michigan; Galveston, Texas
- 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent AlbuminuriaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00287183 · 110 participants · Start Feb 2006 · Primary completion Aug 2009
Drug: PF-04494700 (TTP488) · For: Diabetic Nephropathy
Sites: Red Deer, Canada; Penticton, Canada; Vancouver, Canada · 19 sites in all
- Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade GliomasNot yet recruiting
Akshitkumar MIstryAcademic, hospital or other
NCT07694089 · 80 participants (planned) · Start Oct 1, 2026 · Primary completion Aug 1, 2029
Drug: Dexamethasone; Azeliragon · For: High-grade Gliomas (HGG)
Sites: Louisville, Kentucky · 2 sites in all
Georgetown UniversityAcademic, hospital or other
NCT05256745 · 48 participants (planned) · Start Jun 6, 2023 · Primary completion Dec 2026
Drug: TTP488; ddAC/ddT and 3 more · For: Cancer Related Cognitive Decline; Non-metastatic Breast Cancer
Sites: Washington D.C., District of Columbia; Hackensack, New Jersey · 3 sites in all
- Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain MetastasesSuspended
Baptist Health South FloridaAcademic, hospital or other
NCT05789589 · 46 participants (planned) · Start Nov 17, 2023 · Primary completion Mar 16, 2027
Drug: Azeliragon; Corticosteroid · For: Cancer; Metastasis; Metastatic Cancer and 2 more
Sites: Miami, Florida
- Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose ToleranceTerminated
vTv TherapeuticsIndustry
NCT03980730 · 43 participants · Start Jun 27, 2019 · Primary completion Dec 1, 2020
Drug: Azeliragon; Placebo · For: Alzheimer Disease
Sites: Tucson, Arizona; New Haven, Connecticut; Atlantis, Florida · 33 sites in all
Stefan HeberAcademic, hospital or other
NCT07092215 · 42 participants · Start Jun 17, 2025 · Primary completion Jul 11, 2025
Drug: Synthetic interstitial fluid (SIF) / SIF neutral pH; Synthetic interstitial fluid (SIF) / SIF acidic pH and 8 more · For: Pain
Sites: Vienna, Austria
Cantex PharmaceuticalsIndustry
NCT05635734 · 33 participants · Start Sep 5, 2023 · Primary completion Apr 30, 2026
Drug: Azeliragon 5 mg; Azeliragon 10 mg and 1 more · For: Glioblastoma
Sites: Barcelona, Spain; Madrid, Spain · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Brown Algal Phlorotannin Dieckol Attenuates Amyloid-β Oligomer-Induced Oxidative DNA Damage and Senescence-like Stress in Human Neuron-like Cells.
Lee YR, Lai MC, Tzeng YS, et al. · Mar Drugs 2026
- RAGE mediates LPS-induced inflammatory pain in human skin - a double-blind, randomised, placebo-controlled full crossover study.
Resch FJ, Pramhas S, Jilma B, et al. · Nat Commun 2026
- Targeting the S100A2-RAGE Pathway Restores AT2 Cell Identity and Mitigates Lung Fibrosis.
Zhou C, Wellmerling JH, Bagherpoor AJ, et al. · Am J Respir Cell Mol Biol 2026
- Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer.
Luque M, Morales-Gallego M, Sanz-Álvarez M, et al. · Neoplasia 2026
- Repurposing Azeliragon as a novel antibacterial agent against methicillin-resistant Staphylococcus aureus via combined membrane phospholipids and cell wall targeting.
Ma J, Xia Y, Lin J, et al. · Commun Biol 2026
- Protective effects of the RAGE inhibitor azeliragon as a potential anti-Streptococcus pneumoniae therapeutic in sepsis models.
Zhang L, Lu H, Zhou H · Front Med (Lausanne) 2026
Also in development for Glioblastoma
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- INO-5401Phase 22 trials
Inovio Pharmaceuticals · Glioblastoma, Urothelial Carcinoma
- MT-125Phase 22 trials
Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.